Choosing between doctors and payors in the “buy-and-bill” sector used to be easy – price to the doctor’s advantage. The higher the price, the larger the spread and the happier the drug company. Regeneron is bending that model towards the reimbursers (and Medicare, in particular) with Eylea. Regenero
It’s not often that a biotech executive team talks to the Centers for Medicare & Medicaid Services through a conference call announcing the approval of the company’s first product.
That’s what the Regeneron Pharmaceuticals Inc. team did repeatedly during an early evening call on November 18 following the...
Create an account to read this article
Already a subscriber?
Bristol Myers Squibb’s Opdivo and Merck's Welireg also could benefit from the delay in Medicare price negotiation process eligibility.
Japan looks set to press ahead with a reimbursement price cut for Eisai's Alzheimer's drug Leqembi following a cost-effectiveness review, despite differences with the company over methodology.
The plan was announced as the White House Office of Management and Budget discusses with stakeholders a widely anticipated guidance about the 340B rebate model, which is being advanced by manufacturers to enhance transparency and control ballooning discounts in the program.
Nearshoring production and diversifying contract manufacturing networks can help companies stave off cost increases that will be reflected in higher medicine prices.
A new PBM reform package has familiar provisions, but stakeholders want it to move as a stand-alone bill, rather than as part of a larger legislative vehicle.
Patient access to mental health drugs also will be challenged by the policies in the new budget reconciliation legislation.
States also agreed to fund patient travel to specialized treatment centers as part of their participation in the Medicaid demo of CMS-negotiated outcomes-based contracts for Vertex/CRISPR's Casgevy and bluebird bio's Lyfgenia.
